Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[COVID-19 and people followed for breast cancer: French guidelines for clinical practice of Nice-St Paul de Vence, in collaboration with the Collège Nationale des Gynécologues et Obstétriciens Français (CNGOF), the Société d'Imagerie de la Femme (SIFEM), the Société Française de Chirurgie Oncologique (SFCO), the Société Française de Sénologie et Pathologie Mammaire (SFSPM) and the French Breast Cancer Intergroup-UNICANCER (UCBG)].
Gligorov J, Bachelot T, Pierga JY, Antoine EC, Balleyguier C, Barranger E, Belkacemi Y, Bonnefoi H, Bidard FC, Ceugnart L, Classe JM, Cottu P, Coutant C, Cutuli B, Dalenc F, Darai E, Dieras V, Dohollou N, Giacchetti S, Goncalves A, Hardy-Bessard AC, Houvenaeghel G, Jacquin JP, Jacot W, Levy C, Mathelin C, Nisand I, Petit T, Petit T, Poncelet E, Rivera S, Rouzier R, Salmon R, Scotté F, Spano JP, Uzan C, Zelek L, Spielmann M, Penault-Llorca F, Namer M, Delaloge S. Gligorov J, et al. Among authors: dohollou n. Bull Cancer. 2020 May;107(5):528-537. doi: 10.1016/j.bulcan.2020.03.008. Epub 2020 Apr 1. Bull Cancer. 2020. PMID: 32278467 Free PMC article. French. No abstract available.
[Surveillance Bulletin 2007. Guidelines for clinical practice: management of patients with malignant epithelial tumors of the ovary. First line medical treatment].
Lhommé C, Planchamp F, Joly F, Leblanc E, Albin N, Alliot C, Auclerc G, Cappiello M, Chaigneau L, Delva R, Dohollou N, Guillemet C, Misset JL, Ray-Coquard I, Rhliouch H, Touboul E, Tournigand C; groupe de travail SOR. Lhommé C, et al. Among authors: dohollou n. Bull Cancer. 2007 Dec;94(12):1093-106. doi: 10.1684/bdc.2007.0523. Bull Cancer. 2007. PMID: 18156120 Free article. Review. French. No abstract available.
[Node negative breast cancer. Beyond international consensus: a pragmatic approach].
Penault-Llorca F, Coeffic D, Delozier T, Dohollou N, Freyer G, Gligorov J, Hardy-Bessard AC, Jacot W, Misset JL, Nabholtz JM, Petit T, Spielmann M, Namer M. Penault-Llorca F, et al. Among authors: dohollou n. Bull Cancer. 2011 Jul;98(7):807-25. doi: 10.1684/bdc.2011.1395. Bull Cancer. 2011. PMID: 21727059 Free article. French.
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; PHARE trial investigators. Pivot X, et al. Lancet Oncol. 2013 Jul;14(8):741-8. doi: 10.1016/S1470-2045(13)70225-0. Epub 2013 Jun 11. Lancet Oncol. 2013. PMID: 23764181 Clinical Trial.
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.
Gonçalves A, Pierga JY, Ferrero JM, Mouret-Reynier MA, Bachelot T, Delva R, Fabbro M, Lerebours F, Lotz JP, Linassier C, Dohollou N, Eymard JC, Leduc B, Lemonnier J, Martin AL, Boher JM, Viens P, Roché H. Gonçalves A, et al. Among authors: dohollou n. Ann Oncol. 2015 Aug;26(8):1692-7. doi: 10.1093/annonc/mdv216. Epub 2015 May 5. Ann Oncol. 2015. PMID: 25943350 Free article. Clinical Trial.
New advances in DPYD genotype and risk of severe toxicity under capecitabine.
Etienne-Grimaldi MC, Boyer JC, Beroud C, Mbatchi L, van Kuilenburg A, Bobin-Dubigeon C, Thomas F, Chatelut E, Merlin JL, Pinguet F, Ferrand C, Meijer J, Evrard A, Llorca L, Romieu G, Follana P, Bachelot T, Chaigneau L, Pivot X, Dieras V, Largillier R, Mousseau M, Goncalves A, Roché H, Bonneterre J, Servent V, Dohollou N, Château Y, Chamorey E, Desvignes JP, Salgado D, Ferrero JM, Milano G. Etienne-Grimaldi MC, et al. Among authors: dohollou n. PLoS One. 2017 May 8;12(5):e0175998. doi: 10.1371/journal.pone.0175998. eCollection 2017. PLoS One. 2017. PMID: 28481884 Free PMC article.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Venat-Bouvet L, Cany L, Catala S, Khayat D, Gambotti L, Pauporté I, Faure-Mercier C, Paget-Bailly S, Henriques J, Grouin JM; PHARE trial investigators. Pivot X, et al. Lancet. 2019 Jun 29;393(10191):2591-2598. doi: 10.1016/S0140-6736(19)30653-1. Epub 2019 Jun 6. Lancet. 2019. PMID: 31178155 Clinical Trial.
UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.
D'Hondt V, Canon JL, Roca L, Levy C, Pierga JY, Le Du F, Campone M, Desmoulins I, Goncalves A, Debled M, Rios M, Ferrero JM, Serin D, Hardy-Bessard AC, Piot G, Brain E, Dohollou N, Orfeuvre H, Lemonnier J, Roché H, Delaloge S, Dalenc F. D'Hondt V, et al. Among authors: dohollou n. Eur J Cancer. 2019 Nov;122:91-100. doi: 10.1016/j.ejca.2019.09.014. Epub 2019 Oct 18. Eur J Cancer. 2019. PMID: 31634648 Clinical Trial.
51 results